Xarelto offers an easy universal dose that does not require monitoring or lifestyle restrictions. It quickly became a preferred treatment among all patients, including those who were seriously at risk of stroke, pulmonary embolism and deep vein thrombosis. Over 1.4 million patients have been treated with Xarelto since its debut in 2011.
Despite the drug’s obvious advantages and popularity, FDA panels continually stated that there wasn’t enough data and that the benefits may outweigh the risk. More than 7,000 Xarelto lawsuits have been filed, alleging serious side effects tied to the drug, such as uncontrolled bleeding that required hospitalization, disabling abdominal cramping, and even death. Unlike other drugs of its class, Xarelto has no known antidote to reverse adverse effects.
Since the Xarelto’s release, the FDA has required
multiple updates to the label warning users of